Literature DB >> 2159925

The metabolism of ribavirin in erythrocytes and nucleated cells.

T Page1, J D Connor.   

Abstract

1. The metabolism of the broad-spectrum antiviral drug ribavirin was examined in intact human erythrocytes, cultured skin fibroblasts and EBV-transformed lymphoblasts. At an extracellular ribavirin concentration of 35 microM all the cell types produced ribavirin mono-, di- and triphosphate, with the nucleotide concentration reaching half-maximum in 210, 245 and 267 min for fibroblasts, lymphoblasts and erythrocytes, respectively. The ratio of mono-, di- and triphosphates was ca 4:1:40 in fibroblasts, 3:1:8 in lymphoblasts and 1:5:17 in erythrocytes. 2. When ribavirin was removed from the medium, the half-life of ribavirin nucleotides was less than 2 hr in fibroblasts and lymphoblasts, but greater than 24 hr in erythrocytes. 3. In energy-starved erythrocytes, the catabolism of ribavirin nucleotides closely followed the catabolism of adenine nucleotides. 4. None of these cell types excreted appreciable amounts of the ribavirin catabolites triazole carboxamide, triazole carboxylate or triazole carboxylate ribonucleoside. 5. Cells deficient in adenosine kinase produced greater than 4% of the ribavirin nucleotides of normal controls. 6. The nucleated cells quickly hydrolyzed ribavirin 5'monophosphate to ribavirin, whereas this activity was negligible in erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159925     DOI: 10.1016/0020-711x(90)90140-x

Source DB:  PubMed          Journal:  Int J Biochem        ISSN: 0020-711X


  45 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Mohammad A B Al-Freah; Zeino Zeino; Michael A Heneghan
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Li-Tain Yeh; Trong Luu; David Lourenco; Johnson Y N Lau
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

3.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

Review 4.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

5.  Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection.

Authors:  Liviawati S Wu; Joseph E Rower; James R Burton; Peter L Anderson; Kyle P Hammond; Fafa Baouchi-Mokrane; Gregory T Everson; Thomas J Urban; David Z D'Argenio; Jennifer J Kiser
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 6.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

7.  Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate.

Authors:  Laurent Volpon; Michael J Osborne; Hiba Zahreddine; Andrea A Romeo; Katherine L B Borden
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

Review 8.  Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach.

Authors:  Kenneth E Sherman
Journal:  Clin Infect Dis       Date:  2012-07-26       Impact factor: 9.079

9.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.